Umoja Biopharma Initiates Phase 1/2 Trials for In Vivo CAR-T Therapies UB-VV400 and UB-VV500 Targeting B-Cell Malignancies and Multiple Myeloma

August 9, 2026

Gene Therapy Net (ClinicalTrials.gov) USA

Overview

Umoja Biopharma is set to initiate Phase 1/2 clinical trials for its investigational in vivo CAR-T cell therapies, UB-VV400 for recurrent/refractory B-cell malignancies and UB-VV500 for multiple myeloma, with planned co-administration of rapamycin. This innovative approach aims to generate CAR-expressing T cells directly within the patient’s body, circumventing the logistical complexities and access limitations of conventional ex vivo CAR-T manufacturing. These trials represent a critical step towards expanding CAR-T therapy accessibility and applicability across a broader range of hematologic cancers.

In Depth

Key Findings

Umoja Biopharma has announced the impending initiation of Phase 1/2 clinical trials for its novel in vivo CAR-T cell therapy candidates, UB-VV400 and UB-VV500. UB-VV400 is slated for recurrent and refractory B-cell malignancies, while UB-VV500 targets multiple myeloma. These trials mark a significant advancement in cell therapy, moving towards an ‘in vivo’ approach that eliminates the need for ex vivo manufacturing, potentially broadening patient access to CAR-T therapies.

Technical / Clinical Details

UB-VV400 and UB-VV500 are designed to induce the expression of chimeric antigen receptors (CARs) on T cells directly within the patient’s body. This approach involves delivering genes encoding the CAR directly to target cells, thereby bypassing the intricate processes of T-cell apheresis, ex vivo gene transduction, expansion, and reinfusion characteristic of traditional CAR-T therapies. Both trials will evaluate the safety, tolerability, and preliminary efficacy of UB-VV400 and UB-VV500 when co-administered with rapamycin, an immunosuppressant. This combination strategy aims to optimize the in vivo proliferation and persistence of CAR-T cells while potentially mitigating immunogenicity. UB-VV400 is specifically engineered for B-cell malignancies, and UB-VV500 is tailored for multiple myeloma.

Background & Context

While conventional ex vivo CAR-T cell therapies have demonstrated remarkable success in lymphoproliferative hematologic malignancies, their complex manufacturing processes, high costs, extended lead times, and logistical challenges severely limit patient access. In vivo CAR-T cell therapy is envisioned as a next-generation solution to overcome these bottlenecks, accelerating the widespread adoption of these life-saving treatments. Umoja Biopharma’s pioneering efforts are at the forefront of this paradigm shift, demonstrating the potential to expand CAR-T cell therapy into solid tumors and a wider spectrum of hematologic cancers, addressing unmet clinical needs.

Strategic Significance & Outlook

The outcomes of these Phase 1/2 trials will be crucial for validating the feasibility and therapeutic potential of the in vivo CAR-T cell therapy platform. Successful results could usher in a new era for CAR-T treatment, making it more readily available and affordable for a larger patient population. The application of CAR-T cell therapy to solid tumors, a major hurdle for current approaches, is a key focus, and the development of UB-VV400 and UB-VV500 represents a vital step in addressing this challenge. Favorable safety and preliminary efficacy data will pave the way for larger-scale clinical investigations and accelerate progress towards potential regulatory approval, significantly impacting the future landscape of oncology treatments.

Source: http://www.genetherapynet.com/clinicaltrialsgov.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.